文献速递头颈外科

复发性喉癌的挽救性手术治疗

Salvage surgery for recurrent larynx cancer.
PubMed 文献 · Head Neck · 2019-08-21

回顾性分析1999至2016年Memorial Sloan Kettering癌症中心收治的241例复发性喉癌患者,88%为男性,中位年龄67岁,71%为原发声门肿瘤。2年和5年疾病特异性生存率分别为74%和57%。

要点

  • 复发性喉癌挽救性手术可获得可接受的肿瘤学结局,2年和5年DSS分别为74%和57%。
  • cT4病变接受非手术原发治疗者5年DSS为0%,提示此类患者预后极差。
  • 肿瘤部位、神经周围侵犯、切缘和分期是DSS的独立预测因素。

核心结论

  • 挽救性手术治疗复发性喉癌可获得可接受的肿瘤学结局。
  • 分期、病变部位、神经周围侵犯和切缘与较差的疾病特异性生存相关。

研究设计与样本

  • 回顾性队列研究,纳入1999至2016年在Memorial Sloan Kettering(MSK)治疗的241例复发性喉癌患者。
  • 分析生存结局,中位年龄67岁,88%为男性,71%为原发声门肿瘤。

主要发现

  • 初次治疗时72%患者为早期病变,原发治疗为放疗(68%)、放化疗(29%)和手术(3%)。
  • 2年和5年疾病特异性生存率(DSS)分别为74%和57%。
  • cT4病变接受非手术原发治疗的患者5年DSS为0%。
  • DSS的独立预测因素包括肿瘤部位、神经周围侵犯、切缘和分期。

临床怎么用

  • 对复发性喉癌患者,挽救性手术是可行的治疗选择,但需根据分期、部位、神经周围侵犯和切缘评估预后。
  • cT4病变接受非手术原发治疗者挽救性手术预后极差,临床决策需综合考虑。

局限性

  • 回顾性研究,可能存在选择偏倚。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in treatment, the recurrence rates for laryngeal cancer range from 16% to 40%. METHODS: Patients with recurrent laryngeal cancer treated at Memorial Sloan Kettering (MSK) from 1999 to 2016 were reviewed. Survival outcomes were analyzed. RESULTS: Of 241 patients, 88% were male; the median age was 67 years; 71% had primary glottic tumors. At initial treatment, 72% of patients were seen with early stage disease; primary treatment was radiation (68%), chemoradiation (29%), and surgery (3%). The most common salvage surgery was total laryngectomy (74%). Forty-seven percentage were upstaged at salvage surgery. The 2- and 5-year disease-specific survival (DSS) was 74% and 57%, respectively. Patients with cT4 disease treated with nonsurgical primary management had a 0% 5-year DSS. Independent predictors of DSS were tumor location, perineural invasion, margin, and stage. CONCLUSIONS: Salvage surgery results in acceptable oncologic outcomes. Stage, disease site, perineural invasion, and margins are associated with inferior DSS.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Mimica X, Hanson M, Patel SG, et al. Salvage surgery for recurrent larynx cancer. Head Neck. 2019. PMID: 31433540. doi:10.1002/hed.25925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。